SCHEMBL1120015

SCHEMBL1120015

CCN(CC)C1CCN(C(C(=O)OC)c2ccc(C=CC(=O)Nc3ccccc3NC(=O)OC(C)(C)C)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.38
NPC1 O15118 4/20 0.38
POLB P06746 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.38
CYP2C9 P11712 1/20 0.38
TRPV1 Q8NER1 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
KDM1A O60341 1/20 0.36
TRPA1 O75762 3/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
TNIK Q9UKE5 1/20 0.35
EGFR P00533 2/20 0.35
MMP1 P03956 2/20 0.35
MMP2 P08253 2/20 0.35
MMP9 P14780 2/20 0.35
HDAC3 O15379 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1120014 1.00 RAB9A (0.38) RAB9ANPC1POLBCYP1A2CYP3A4
SCHEMBL1119717 0.93 EGFR (0.37) RAB9ANPC1POLBCYP1A2CYP3A4
SCHEMBL1119718 0.93 EGFR (0.37) RAB9ANPC1POLBCYP1A2CYP3A4
SCHEMBL1119722 0.87 TRPV1 (0.40) RAB9ANPC1POLBCYP1A2CYP3A4
SCHEMBL1119720 0.87 TRPV1 (0.40) RAB9ANPC1POLBCYP1A2CYP3A4
SCHEMBL2243820 0.87 TRPV1 (0.40) RAB9ANPC1POLBCYP1A2CYP3A4
SCHEMBL2243831 0.87 TRPV1 (0.40) RAB9ANPC1POLBCYP1A2CYP3A4
SCHEMBL12356628 0.83 ALDH1A1 (0.49) RAB9ANPC1POLBCYP1A2CYP3A4
SCHEMBL1120016 0.83 TRPM8 (0.38) MEN1KMT2ATRPM8ALDH1A1LMNA
SCHEMBL2248634 0.80 TRPV1 (0.39) RAB9ANPC1POLBCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999000-B2 N-(2-amino-phenyl)-acrylamides HOFFMANN-LA ROCHE INC. (US) 2011-08-16 US disclosed
EP-2280940-A1 NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES F. Hoffmann-La Roche AG (CH) 2011-02-09 EP disclosed
WO-2009138338-A1 NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2009-11-19 WO disclosed
US-20090286848-A1 NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES HOFFMANN-LA ROCHE INC. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286848-A1 NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES MKI67, CCNA2, CCNA1 RAB9A 3938/4885NPC1 3656/4885POLB 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.